POST Online Media Lite Edition



 

Novartis giving $1.6 billion to get access to two cardio drugs

Staff Writer |
Novartis has agreed to pay up to $1.6 billion to Ionis Pharmaceuticals and its unit Akcea Therapeutics for the rights to two cardiovascular drugs.

Article continues below






The deal involves an upfront payment to Iona and Akcea of $75 million plus a $100 million equity investment in Iona.

Novartis has also agreed to invest a further $50 million in either Ionis or Akcea within 18 months, as well as payments worth up to $1.4 billion should the drugs prove successful.

Both drugs aim to lower the level of cholesterol-carrying proteins in the blood and reduce the risk of certain cardiovascular diseases developing.


What to read next

Novartis chairman thinking about sale of Alcon eye care division
Novartis is buying ofatumumab from GSK for $1 billion
Novartis splits drugs business into two